FDA will require quality metrics reporting by rule rather than by guidance, the agency said Nov. 25 in revised draft guidance on its quality metrics program.
The revised draft establishes a pilot program stripped of controversial elements that will give FDA and the pharmaceutical industry practice with this novel type of agency-industry
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?